Full year 2016

Another year of double-digit sales growth for Tecan

Tecan Group AG / Full year 2016: Another year of double-digit sales growth for Tecan . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Financial results: full-year and second half of 2016

• Order entry of CHF 503.2 million (2015: CHF 465.0 million)
  • Full-year growth of 6.9% in local currencies or 8.2% in Swiss francs
  • Strong H2 growth in Life Sciences Business, supported by new products
  • H2 growth in Partnering Business impacted by one large order shifted to January 2017
• Sales of CHF 506.2 million (2015: CHF 440.3 million)
  • Full-year growth of 13.5% in local currencies or 15.0% in Swiss francs
  • Full-year organic growth of 8.2% in local currencies and 9.6% in Swiss francs
  • H2 sales growth of 12.2% in local currencies or 12.7% in Swiss francs
• Full-year operating profit before depreciation and amortization (EBITDA) of CHF 89.0 million (2015: CHF 83.4 million)
  • Reported EBITDA margin of 17.6% (2015: 18.9%), including acquisition-related costs and reduced margins associated with the acquisition of Sias AG
  • Underlying EBITDA, excluding acquisition-related effects, of CHF 93.2 million
  • Strong improvement in underlying EBITDA margin of 140 basis points to 19.5% (2015: 18.1%), driven by positive volume and price effects as well as substantial efficiency improvements
• Full-year net profit of CHF 54.5 million below prior year due to integration costs and non-operational effects (2015: CHF 57.1 million)
  • Net profit margin including integration costs of 10.8% (2015: 13.0%)
  • Earnings per share of CHF 4.74 (2015: CHF 5.05)
• Strong full-year cash flow from operating activities of CHF 118.8 million (2015: CHF 99.1 million) or 23.5% of sales (2015: 22.5%)

Operating highlights 2016 and other important information